The results illuminated that SPRED1 expression levels were decreased upon E2 treatment, and ER-α, but not ER-β inhibition dramatically reversed SPRED1 levels regardless the presence of E2 in ER+ BC cells (Fig. 6e and f). The gene discussed is ESR2; the disease is breast cancer.